In the US, Toremifene (toremifene systemic) is a member of the following drug classes: hormones/antineoplastics, selective estrogen receptor modulators and is used to treat Breast Cancer and Breast Cancer - Metastatic.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Antineoplastic agent: Antiestrogen
- Toremifenum (Latin)
- Toremifen (German)
- Torémifène (French)
- Toremifeno (Spanish)
- Toremifene (OS: BAN)
- Torémifène (OS: DCF)
- FC 1157 (IS: FarmosGroupLt)
- Toremifene Citrate (OS: USAN, JAN)
- FC 1157a (IS: FarmosGroupLt)
Orion, Egypt; Orion, Georgia; Orion, Greece; Orion, Lebanon; Orion, Poland; Schering-Plough, South Africa; Baxter Oncology, Germany; CSP, France; Dong-A, South Korea; Merck Sharp & Dohme, Australia; Merck Sharp & Dohme, New Zealand; Nippon Kayaku, Japan; Orion, China; Orion, Czech Republic; Orion, Ireland; Orion, Lithuania; Orion, Portugal; Orion, Romania; Orion Pharma, Finland; Orion Pharma, Sweden; ProStrakan, United States; Schering-Plough, Spain; Schering-Plough, Italy
- Shu Rui
- Toremifene Sawai
Medisa Shinyaku, Japan
|BAN||British Approved Name|
|DCF||Dénomination Commune Française|
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.